• +1-646-491-9876
    • +91-20-67278686

    Search

    GTPase KRas-Pipeline Review H1 2017

    GTPase KRas-Pipeline Review H1 2017

    • Report Code ID: RW0001834431
    • Category Pharmaceuticals
    • No. of Pages 54
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H1 2017

    Summary

    According to the recently published report 'GTPase KRas - Pipeline Review, H1 2017'; GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) pipeline Target constitutes close to 23 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.

    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - KRAS is a GTPase encoded by the KRAS gene. It plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner.

    The report 'GTPase KRas - Pipeline Review, H1 2017' outlays comprehensive information on the GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviewsalso reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 9 and 9 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Lung Cancer, Pancreatic Cancer, Colon Cancer, Colorectal Cancer, Small-Cell Lung Cancer and Solid Tumor.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
    - The report reviews GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics and enlists all their major and minor projects
    - The report assesses GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Overview
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    Aurigene Discovery Technologies Ltd
    Boehringer Ingelheim GmbH
    Critical Outcome Technologies Inc
    Horizon Discovery Group Plc
    Mirati Therapeutics Inc
    Nuevolution AB
    PeptiDream Inc
    Takeda Pharmaceutical Company Ltd
    Tosk Inc
    Warp Drive Bio Inc
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Drug Profiles
    Antibody to Inhibit KRAS for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARS-853 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-4785 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    COTI-219 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HD-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KRpep-2d - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MM-41 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit KRAS for Pancreatic Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotide to Inhibit KRAS for Lung Cancer and Colon Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit K-RAS for Non-Small Cell Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit KRAS for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit KRAS for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules 1 to Inhibit K-Ras for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules 2 to Inhibit K-Ras for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules 3 to Inhibit K-Ras for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit K Ras for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit K-Ras for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit KRAS for Non-Small Cell Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit KRAS for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit KRAS2B for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SML-8731 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Inhibit KRAS for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target K-RAS for Lung Cancer - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Dormant Products
    GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Product Development Milestones
    Featured News & Press Releases
    Dec 16, 2016: Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
    Oct 11, 2016: Critical Outcome Technologies Announces Next Clinical Candidate, COTI-219, Targeting KRAS
    Jul 29, 2014: Researchers Identify Irreversible Inhibitor for KRAS Gene Mutation
    May 08, 2013: Sentinel Oncology Achieves Milestone In Horizon Discovery Agreement
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
    Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Pipeline by Critical Outcome Technologies Inc, H1 2017
    Pipeline by Horizon Discovery Group Plc, H1 2017
    Pipeline by Mirati Therapeutics Inc, H1 2017
    Pipeline by Nuevolution AB, H1 2017
    Pipeline by PeptiDream Inc, H1 2017
    Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Pipeline by Tosk Inc, H1 2017
    Pipeline by Warp Drive Bio Inc, H1 2017
    Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AstraZeneca Plc
    Aurigene Discovery Technologies Ltd
    Boehringer Ingelheim GmbH
    Critical Outcome Technologies Inc
    Horizon Discovery Group Plc
    Mirati Therapeutics Inc
    Nuevolution AB
    PeptiDream Inc
    Takeda Pharmaceutical Company Ltd
    Tosk Inc
    Warp Drive Bio Inc

    Request for Sample

    Report Url http://www.reportsweb.com//gtpase-kras-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//gtpase-kras-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//gtpase-kras-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments